Miplyffa (Arimoclomol Citrate) Patent Expiration, LOE Window & CMS Spending

Miplyffa (Arimoclomol Citrate) by Zevra Denmark As: FDA Orange Book core substance LOE 2041-11-19, 0 AB generics, $3.1M 2024 CMS Part D & Medicaid spend, and $106,020 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorZevra Denmark As
FDA Application & PathwayN214927 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-11-19
Last Listed Patent or Exclusivity Date2041-11-19
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.1M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($106,020 intro WAC)